特朗普国情咨文重提医保亮点,却无新政出台。
Trump’s State of the Union trumpets healthcare greatest hits, but no new policies
生物技术与制药领域的最新动态
Trump’s State of the Union trumpets healthcare greatest hits, but no new policies
Alkermes’ Richard Pops to step down after three-decade run as CEO
GSK to acquire 35Pharma in $950M deal for cardiovascular drug
15 states sue HHS over changes to childhood vaccine schedule
With Vivtex deal, Novo gains a chance at better oral obesity drugs
BreezeBio banks $60M to make more precise genetic medicines
Vir climbs on Astellas deal, study results for ‘masked’ T cell engager
Novo to cut GLP-1 drug prices; Palvella soars on study data
Novo, searching for a spark, spotlights new data for three-pronged obesity drug
Slate starts up with $130M and a headache drug from China
FDA fleshes out new roadmap for testing personalized therapies
Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Merck to split cancer, specialty drug businesses in leadership shakeup
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy
All about cell therapy process characterization
Grail’s multi-cancer early detection test misses study goal
Supreme Court invalidates Trump tariffs based on emergency powers
Roche gets FDA decision date on closely watched breast cancer drug
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
AI is slashing jobs across industries. Will pharma be next?